TY - JOUR
T1 - Prognostication of progressive pulmonary fibrosis in connective tissue disease-associated interstitial lung diseases
T2 - A cohort study
AU - Chiu, Yu Hsiang
AU - Koops, Maaike F.M.
AU - Voortman, Mareye
AU - van Es, H. Wouter
AU - Langezaal, Lucianne C.M.
AU - Welsing, Paco M.J.
AU - Jamnitski, Anna
AU - Wind, Anne E.
AU - van Laar, Jacob M.
AU - Grutters, Jan C.
AU - Spierings, Julia
N1 - Funding Information:
We want to thank the health professional at the ILD Center of Excellence, St. Antonius Hospital, Nieuwegein, Netherlands and all patients who participated in this study.
Publisher Copyright:
Copyright © 2023 Chiu, Koops, Voortman, van Es, Langezaal, Welsing, Jamnitski, Wind, van Laar, Grutters and Spierings.
PY - 2023/2/27
Y1 - 2023/2/27
N2 - BACKGROUND: Connective tissue diseases-associated interstitial lung disease (CTD-ILD) is a heterogeneous condition that impairs quality of life and is associated with premature death. Progressive pulmonary fibrosis (PPF) has been identified as an important risk factor for poor prognosis. However, different criteria for PPF are used in clinical studies, which may complicate comparison between trials and translation of study findings into clinical practice.METHODS: This is a retrospective single center study in patients with CTD-ILD. The prognostic relevance of PPF definitions, including INBUILD, ATS/ERS/JRS/ALAT 2022, and simplified progressive fibrosing (simplified PF) criteria, were examined in this cohort and validated in the other reported Dutch CTD-ILD cohort.RESULTS: A total of 230 patients with CTD-ILD were included and the median follow-up period was six (3-9) years. Mortality risk was independently associated with age (adjusted HR 1.07,
p < 0.001), smoking history (adjusted HR 1.90,
p = 0.045), extent of fibrosis on high-resolution computed tomography (HRCT) at baseline (adjusted HR 1.05,
p = 0.018) and baseline DLCO (adjusted HR 0.97,
p = 0.013). Patients with regular pulmonary function tests in the first 2 years (adjusted HR 0.42,
p = 0.002) had a better survival. The prognostic relevance for survival was similar between the three PPF criteria in the two cohorts.
CONCLUSION: Higher age, smoking, increased extent of fibrosis and low baseline DLCO were associated with poor prognosis, while regular pulmonary function evaluation was associated with better survival. The INBUILD, ATS/ERS/JRS/ALAT 2022, and simplified PF criteria revealed similar prognostication.
AB - BACKGROUND: Connective tissue diseases-associated interstitial lung disease (CTD-ILD) is a heterogeneous condition that impairs quality of life and is associated with premature death. Progressive pulmonary fibrosis (PPF) has been identified as an important risk factor for poor prognosis. However, different criteria for PPF are used in clinical studies, which may complicate comparison between trials and translation of study findings into clinical practice.METHODS: This is a retrospective single center study in patients with CTD-ILD. The prognostic relevance of PPF definitions, including INBUILD, ATS/ERS/JRS/ALAT 2022, and simplified progressive fibrosing (simplified PF) criteria, were examined in this cohort and validated in the other reported Dutch CTD-ILD cohort.RESULTS: A total of 230 patients with CTD-ILD were included and the median follow-up period was six (3-9) years. Mortality risk was independently associated with age (adjusted HR 1.07,
p < 0.001), smoking history (adjusted HR 1.90,
p = 0.045), extent of fibrosis on high-resolution computed tomography (HRCT) at baseline (adjusted HR 1.05,
p = 0.018) and baseline DLCO (adjusted HR 0.97,
p = 0.013). Patients with regular pulmonary function tests in the first 2 years (adjusted HR 0.42,
p = 0.002) had a better survival. The prognostic relevance for survival was similar between the three PPF criteria in the two cohorts.
CONCLUSION: Higher age, smoking, increased extent of fibrosis and low baseline DLCO were associated with poor prognosis, while regular pulmonary function evaluation was associated with better survival. The INBUILD, ATS/ERS/JRS/ALAT 2022, and simplified PF criteria revealed similar prognostication.
KW - connective tissue diseases
KW - immune-mediated inflammatory diseases
KW - interstitial lung diseases
KW - outcome predictors
KW - pulmonary fibrosis
UR - https://www.scopus.com/pages/publications/85150064984
U2 - 10.3389/fmed.2023.1106560
DO - 10.3389/fmed.2023.1106560
M3 - Article
C2 - 36923009
AN - SCOPUS:85150064984
SN - 2296-858X
VL - 10
JO - Frontiers in medicine
JF - Frontiers in medicine
M1 - 1106560
ER -